This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Goldie, A. Articles by Edwards, J. G. Search for Related Content PubMed Articles by Goldie, A. Articles by Edwards, J. G. Social Bookmarking                         What's this?

Effect of clovoxamine fumarate on the electrocardiogram

Department of Psychiatry, Royal South Hants Hospital, Southampton SO9 4PE, UK

J. Guy Edwards

Department of Psychiatry, Royal South Hants Hospital, Southampton SO9 4PE, UK

The electrocardiographic effects of clovoxamine, an antidepressant that inhibits the neuronal uptake of both noradrenaline and 5-hydroxytryptamine, have been studied. High speed electrocardiograms were recorded on 28 patients with depressive illness before and after 4 weeks treatment with either clovoxamine or placebo. No patient had clinical evidence of cardiovascular disease. The ECG measurements were carried out blind to patient, treatment and treatment interval. No statistically significant changes in the sinus cycle length, PR, QRS and QTc intervals, or T-wave height were found after treatment with active drug or placebo, showing that clovoxamine has no clinically important effects on the ECG when given in therapeutic doses to patients free from serious physical disease.

Journal of Psychopharmacology, Vol. 3, No. 1, 29-31 (1989)
DOI: 10.1177/026988118900300105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?